Novartis Faces Legal Setbacks as MSN's Entresto Generic Secures Approval

Novartis is fiercely battling to protect its heart failure medication, Entresto, from generic competition after MSN Pharmaceuticals secured approval for a generic version. Their latest legal setback came when a federal appeals court denied Novartis' request for a preliminary injunction to stop MSN's production, following an earlier FDA approval of the generic drug[1]. Novartis argued that MSN's product infringed on its '918 patent and that its release could cause irreparable harm, but both the district court and the U.S. Court of Appeals for the Federal Circuit found these claims unconvincing[1][2]. Despite Entresto's significant contribution to Novartis' revenues, the company is confronting other pressures, such as the anticipated price regulations under the Inflation Reduction Act, starting in 2026, which further threaten its market position[2].